Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations

28 Mar 2022

Abstract excerpt

The bromodomain and extra-terminal (BET) proteins act as “readers” for lysine acetylation and facilitate the recruitment of transcriptional elongation complexes. BET protein is associated with transcriptional elongation of genes such as c-MYC and BCL-2, and is involved in the regulation of cell cycle and apoptosis. Meanwhile, BET inhibitors (BETi) have regulatory effects on immune checkpoints, immune cells, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37554207
DOI: 10.1016/j.gendis.2022.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinationsPMID 37554207Read ↗

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsSemantic proximity Read ↗

Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasmsSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Targeting BET Bromodomains in CancerSemantic proximity Read ↗

Domain-selective targeting of BET proteins in cancer and immunological diseasesSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

Targeting BET Bromodomains for Cancer TreatmentSemantic proximity Read ↗

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsSemantic proximity Read ↗

Post-Translational Modifications of BRD4: Therapeutic Targets for TumorSemantic proximity Read ↗

The Functions of BET Proteins in Gene Transcription of Biology and DiseasesSemantic proximity Read ↗

Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML)Semantic proximity Read ↗

BET inhibitors as novel therapeutic agents in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.